Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2022 | Anti-BCMA lipid-based nanoparticle therapeutic strategy for patients with multiple myeloma

Zahraa Al-Ahmady • 31 Aug 2022
IMS 2022
Multiple Myeloma Antibodies Belantamab mafodotin CAR-T

Zahraa Al-Ahmady, BSc, MSc, PhD, Nottingham Trent University, Nottingham, UK, discusses the feasibility and advantages of a novel anti-BCMA lipid-based nanoparticle therapeutic strategy designed to improve the tolerance and availability of BCMA-directed therapies for patients with multiple myeloma. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals